Bicara Therapeutics Inc. Common Stock (BCAX) is a publicly traded Healthcare sector company. As of May 21, 2026, BCAX trades at $20.43 with a market cap of $1.27B and a P/E ratio of -8.10. BCAX moved +2.05% today. Year to date, BCAX is +26.82%; over the trailing twelve months it is +35.84%. Its 52-week range spans $7.80 to $28.09. Analyst consensus is strong buy with an average price target of $30.99. Rallies surfaces BCAX's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Rallies AI research for BCAX combines live market data, fundamentals, news, analyst context, hedge fund holdings, politician trades, insider activity, and risk factors into a ticker-specific research workflow.
| Metric | Value |
|---|---|
| Price | $20.43 |
| Market Cap | $1.27B |
| P/E Ratio | -8.10 |
| EPS | $-2.52 |
| Dividend Yield | 0.00% |
| 52-Week High | $28.09 |
| 52-Week Low | $7.80 |
| Volume | 4.42K |
| Avg Volume | 0 |
| Revenue (TTM) | $0 |
| Net Income | $-137.95M |
| Gross Margin | 0.00% |
11 analysts cover BCAX: 0 strong buy, 9 buy, 2 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $30.99.